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Background. A	  sizable	  group	  of	  patients	  with	  symptomatic	  aortic	  stenosis	  (AS)	  can	  undergo	  
neither	  surgical	  aortic	  valve	  replacement	  (AVR)	  nor	  transcatheter	  aortic	  valve	  implantation	  
(TAVI)	  because	  of	  clinical	  contraindications.	  The	  aim	  of	  this	  study	  was	  to	  assess	  the	  potential	  
role	  of	  balloon	  aortic	  valvuloplasty	  (BAV)	  as	  a	  “bridge-­‐to-­‐decision”	  	  in	  selected	  patients	  with	  
severe	  AS	  and	  potentially	  reversible	  contraindications	  to	  definitive	  treatment.	   
Methods. We	  retrospectively	  enrolled	  645	  patients	  who	  underwent	  first	  BAV	  at	  our	  
Institution	  between	  July	  2007	  and	  December	  2012.	  Of	  these,	  the	  202	  patients	  (31.2%)	  who	  
underwent	  BAV	  as	  bridge-­‐to-­‐decision	  (BTD)	  requiring	  clinical	  re-­‐evaluation	  represented	  our	  
study	  population.	  BTD	  patients	  were	  further	  subdivided	  in	  5	  groups:	  low	  left	  ventricular	  
ejection	  fraction;	  mitral	  regurgitation	  grade	  ≥3;	  frailty;	  hemodynamic	  instability;	  comorbidity.	  
The	  main	  objective	  of	  the	  study	  was	  to	  evaluate	  how	  BAV	  influenced	  the	  final	  treatment	  
strategy	  in	  the	  whole	  BTD	  group	  and	  in	  its	  single	  specific	  subgroups.	  
Results.	  Mean	  logistic	  EuroSCORE	  was	  23.5±15.3%,	  mean	  age	  was	  81±7	  years.	  Mean	  
transaortic	  gradient	  decreased	  from	  47±17	  mmHg	  to	  33±14	  mmHg.	  Of	  the	  193	  patients	  with	  
BTD-­‐BAV	  who	  received	  a	  second	  heart	  team	  evaluation,	  72.5%	  were	  finally	  deemed	  eligible	  for	  
definitive	  treatment	  (25.4%for	  AVR;	  47.2%	  for	  TAVI):	  respectively,	  96.7%	  of	  patients	  with	  left	  
ventricular	  ejection	  fraction	  recovery;	  70.5%	  of	  patients	  with	  mitral	  regurgitation	  reduction;	  
75.7%	  of	  patients	  who	  underwent	  BAV	  in	  clinical	  hemodynamic	  instability;	  69.2%	  of	  frail	  
patients	  and	  68%	  of	  patients	  who	  presented	  relevant	  comorbidities.	  27.5%	  of	  the	  study	  
population	  was	  deemed	  ineligible	  for	  definitive	  treatment	  and	  treated	  with	  standard	  
therapy/repeated	  BAV.	  In-­‐hospital	  mortality	  was	  4.5%,	  cerebrovascular	  accident	  occurred	  in	  




Conclusions.	  Balloon	  aortic	  valvuloplasty	  should	  be	  considered	  as	  bridge-­‐to-­‐decision	  in	  high-­‐
risk	  patients	  with	  severe	  aortic	  stenosis	  who	  cannot	  be	  immediate	  candidates	  for	  definitive	  
percutaneous	  or	  surgical	  treatment.	  
	  
 






A	  sizable	  proportion	  of	  patients	  with	  severe	  aortic	  stenosis	  (AS)	  have	  clinical	  conditions	  that	  
may	  preclude	  definitive	  treatment	  with	  surgical	  aortic	  valve	  replacement	  (SAVR)	  or	  
transcatheter	  aortic	  valve	  replacement	  (TAVR)1-­‐3.	  With	  the	  possible	  exception	  of	  
haemodynamically	  unstable	  patients	  or	  symptomatic	  patients	  who	  require	  urgent	  major	  non-­‐
cardiac	  surgery,	  current	  guidelines	  do	  not	  support	  the	  use	  of	  percutaneous	  balloon	  aortic	  
valvuloplasty	  (BAV)	  as	  a	  bridge	  to	  SAVR	  or	  TAVR4,5.	  Of	  interest,	  a	  possible	  role	  for	  BAV	  and	  
subsequent	  clinical	  re-­‐evaluation	  has	  been	  proposed	  in	  selected	  patients	  with	  severe	  AS	  and	  
clinical	  conditions	  generating	  uncertainty	  within	  the	  heart	  team	  6,	  but	  there	  are	  virtually	  no	  
data	  supporting	  such	  a	  strategy.	  
	   With	  the	  present	  study	  we	  sought	  to	  evaluate	  the	  role	  of	  BAV	  as	  a	  “bridge-­‐to-­‐decision”	  
in	  selected	  patients	  with	  severe	  AS	  and	  potentially	  reversible	  contraindications	  to	  definitive	  
surgical	  or	  transcatheter	  treatment.	  
 
Methods	  
Patient	  population. All	  consecutive	  patients	  who	  underwent	  BAV	  at	  our	  institutions	  were	  
entered	  in	  a	  prospective	  BAV	  registry.	  Indications	  to	  BAV,	  always	  discussed	  within	  the	  heart	  
team,	  were	  the	  following:	  1)	  Destination	  therapy,	  i.e.	  palliation	  of	  symptoms	  in	  patients	  
without	  other	  therapeutic	  options;	  2)	  bridge-­‐to-­‐TAVR,	  in	  patients	  who	  are	  candidates	  for	  TAVR	  
with	  the	  aim	  of	  improving	  clinical	  conditions	  before	  the	  procedure;	  3)	  bridge-­‐to-­‐AVR,	  in	  
patients	  who	  were	  candidates	  for	  AVR	  in	  order	  to	  improve	  clinical	  status	  or	  reduce	  surgical	  
risk;	  4)	  bridge-­‐to-­‐decision	  BAV	  (BTD),	  when	  there	  was	  either	  severe	  clinical	  instability	  or	  initial	  
heart	  team	  evaluation	  was	  not	  conclusive	  and	  indicated	  the	  necessity	  of	  a	  subsequent	  clinical	  
or	  instrumental	  re-­‐evaluation.	  The	  present	  study	  focuses	  on	  this	  last	  patients’	  group.	  Based	  on	  




retrospectively)	  subdivided	  into	  5	  subgroups	  of	  interest:	  a)	  low	  left	  ventricular	  ejection	  fraction	  
(LVEF≤30%);	  b)	  mitral	  valve	  regurgitation	  (MVR)	  grade	  ≥3;	  c)	  frailty,	  ie	  patients	  with	  a	  
Rockwood	  Frailty	  Index	  =3	  or	  frailty	  index=2	  with	  at	  least	  another	  severe	  comorbidity	  between	  
COPD,	  renal	  failure	  (GFR<	  30	  ml/min),	  BMI	  <20	  o	  >30	  Kg/m2,	  serum	  albumin	  <3.5	  g/dL	  and	  liver	  
cirrhosis;	  d)	  hemodynamic	  instability,	  either	  cardiogenic	  shock	  or	  acute	  pulmonary	  edema	  or	  
NYHA	  class	  IV;	  e)	  comorbidity,	  representing	  a	  potentially	  reversible	  contraindication	  for	  
definitive	  treatment	  per	  se	  or	  in	  combination	  with	  other	  risk	  factors	  (including	  pulmonary	  
hypertension,	  multiple	  comorbidities,	  need	  for	  urgent	  non	  cardiac	  surgery). 
Study	  objectives	  and	  definitions. All	  patients	  had	  ambulatory	  visit	  and	  echocardiography	  
scheduled	  1	  month	  after	  BAV.	  The	  main	  objective	  of	  the	  study	  was	  to	  evaluate	  how	  BAV	  
influenced	  the	  final	  heart	  team	  decision-­‐making	  in	  the	  whole	  BTD	  group	  and	  in	  its	  single	  
specific	  subgroups.	  The	  impact	  of	  BAV	  was	  also	  evaluated	  in	  specific	  subgroups	  of	  interest:	  in	  
patients	  with	  low	  LVEF	  a	  significant	  improvement	  was	  considered	  as	  an	  improvement	  >	  5%	  or	  a	  
final	  LVEF>30%	  in	  conjunction	  with	  subjective	  clear	  clinical	  benefit;	  in	  patients	  with	  MVR	  grade	  
≥3,	  significant	  improvement	  was	  defined	  by	  a	  final	  MVR	  ≤2	  using	  standard	  definitions7.	  Final	  
therapeutic	  decision	  formulated	  by	  the	  heart	  team	  did	  not	  rely	  only	  on	  these	  changes	  but	  took	  
into	  account	  the	  whole	  patient	  status	  and	  life	  expectancy.	  Based	  on	  this	  second	  evaluation,	  
patients	  were	  candidates	  for	  TAVI,	  AVR	  or	  medical	  treatment	  with	  possible	  repeat	  palliative	  
BAV	  (MT/BAV).	  
Symptomatic	  status	  was	  classified	  based	  on	  the	  presence	  of	  syncope,	  stable	  angina,	  acute	  
coronary	  syndrome,	  dyspnea	  (New	  York	  Heart	  Association	  class),	  or	  cardiogenic	  shock.	  
Coronary	  artery	  disease	  included	  previous	  percutaneous	  coronary	  intervention	  (PCI),	  previous	  
coronary	  artery	  bypass	  graft	  (CABG),	  or	  documented	  stenosis	  ≥70%	  of	  a	  major	  coronary	  vessel	  
by	  visual	  estimate	  at	  angiography.	  Chronic	  kidney	  disease	  (CKD)	  was	  identified	  by	  a	  glomerular	  
filtration	  rate	  (GFR)	  calculated	  by	  the	  MDRD	  (Modification	  of	  Diet	  in	  Renal	  Disease)	  formula	  




obstructive	  pulmonary	  disease	  was	  identified	  by	  forced	  expiratory	  volume	  in	  1	  second<1	  liter	  
or	  long-­‐term	  use	  of	  bronchodilators,	  steroids	  or	  oxygen	  for	  lung	  disease.	  Pulmonary	  
hypertension	  was	  defined	  as	  an	  estimated	  systolic	  pulmonary	  pressure	  ≥60	  mmHg	  with	  
echocardiography.	  The	  surgical	  risk	  was	  estimated	  with	  the	  logistic	  EuroSCORE	  (European	  
System	  for	  Cardiac	  Operative	  Risk	  Evaluation).8	  
In-­‐hospital	  events	  measured	  were:	  all-­‐cause	  death,	  cardiac	  death	  (including	  deaths	  not	  clearly	  
due	  to	  extra-­‐cardiac	  causes),	  cerebrovascular	  events	  (stroke,	  transient	  ischemic	  attack),	  
myocardial	  infarction,	  acute	  aortic	  regurgitation,	  and	  vascular	  complications	  (local	  hematoma,	  
retroperitoneal	  hematoma,	  artero-­‐venous	  fistula,	  dissection,	  femoral	  pseudo-­‐aneurysm,	  
thrombosis).	  Stroke	  was	  classified	  as	  disabling	  or	  not	  disabling	  based	  on	  the	  use	  of	  the	  
modified	  Rankin	  Scale.9	  Vascular	  complications	  were	  defined	  major	  (leading	  to	  death,	  life-­‐	  
threatening	  or	  major	  bleeding,	  permanent	  damage	  or	  requiring	  surgery)	  or	  minor	  (including	  
percutaneous	  closure	  device	  failure).	  	  
All	  patients	  signed	  written	  informed	  consent	  for	  the	  procedure	  and	  for	  enrollment	  in	  the	  local	  
BAV	  registry.	  	  
Statistical	  analysis. Continuous	  variables	  were	  expressed	  as	  mean	  ±	  standard	  deviation	  (SD).	  
Categorical	  variables	  were	  presented	  as	  frequencies	  and	  percentages.	  For	  comparisons	  
between	  groups,	  the	  Chi-­‐square	  test	  for	  categorical	  variables	  was	  used.	  Student	  t	  test	  was	  
used	  to	  compare	  continuous	  variables.	  Multivariable	  Cox	  regression	  was	  used	  to	  identify	  
predictors	  of	  definitive	  treatment	  of	  aortic	  stenosis.	  Dichotomous	  variables	  with	  a	  frequency	  
greater	  than	  1%	  and	  all	  continuous	  variables	  were	  selected	  for	  the	  analysis.	  A	  stepwise	  model	  
was	  used	  to	  select	  variables	  for	  the	  final	  model	  (probability	  to	  enter	  the	  model	  =	  probability	  to	  
exit	  from	  the	  model	  =	  0.15).	  All	  tests	  were	  2-­‐sided	  and	  statistical	  significance	  was	  defined	  as	  






Between	  July	  2007	  and	  December	  2012,	  645	  patients	  underwent	  first	  BAV	  at	  our	  institutions.	  
In	  202	  cases	  (31.2%),	  indication	  for	  the	  procedure	  was	  bridge-­‐to-­‐decision,	  which	  represents	  
the	  focus	  of	  this	  study.	  Study	  flow	  is	  reported	  in	  figure	  1.	  	  Demographics,	  clinical	  history	  and	  
baseline	  characteristics	  are	  reported	  in	  Table	  1.	  High-­‐risk	  profile	  is	  confirmed	  by	  advanced	  age	  
(81±7	  years)	  and	  high	  prevalence	  of	  comorbidity,	  including	  coronary	  artery	  disease	  (43.1%),	  
previous	  cardiac	  surgery	  (9.9%),	  severe	  renal	  disease	  (27.2%),	  COPD	  (29.2%)	  and	  high	  logistic	  
EuroSCORE	  (23.5±15.3%).	  Table	  2	  summarizes	  echocardiography	  data	  before	  and	  after	  BAV.	  
Mean	  trans-­‐valvular	  gradient	  decreased	  from	  47±17	  mmHg	  to	  33±14	  mmHg	  and	  AVA	  
increased	  fron	  0.66±0.17	  mm2	  to	  0.84±0.24	  mm2.	  Nine	  patients	  died	  before	  hospital	  discharge,	  
the	  vast	  majority	  (8	  patients)	  presented	  hemodynamic	  instability	  at	  admission.	  The	  incidence	  
of	  other	  complications	  was	  overall	  	  low	  (table	  3).	  All	  193	  surviving	  patients	  were	  re-­‐evaluated	  
at	  outpatient	  clinic	  and	  by	  the	  heart	  team	  around	  1	  month	  later.	  
Patients	  with	  low	  LVEF. A	  significant	  improvement	  in	  LVEF	  was	  observed	  in	  30/44	  surviving	  
patients	  (63.8%).	  Average	  LVEF	  was	  38±7%	  in	  patients	  who	  recovered	  vs.	  26±4%	  (p<0.01)	  in	  
those	  who	  did	  not.	  There	  were	  no	  significant	  differences	  in	  demographics	  and	  clinical	  history,	  
including	  previous	  myocardial	  infarction,	  between	  patients	  who	  recovered	  LVEF	  and	  those	  who	  
did	  not.	  	  Baseline	  LVEF	  was	  also	  similar	  between	  groups	  (28±4	  mmHg	  vs	  26±3	  mmHg,	  
respectively,	  p=0.27),	  as	  well	  as	  baseline	  AVA	  (0.65±0.17	  mm2	  vs.	  0.64±0.15	  mm2,	  p=0.83).	  
Conversely,	  there	  was	  a	  significant	  difference	  in	  baseline	  transvalvular	  gradients	  (mean	  
gradient	  42±16	  mmHg	  vs.	  31±8	  mmHg,	  p=0.03).	  After	  1	  month,	  patients	  who	  recovered	  
showed	  similar	  AVA	  (0.80±0.23	  mm2	  vs.	  0.88±0.21	  mm2,	  p=0.30)	  but	  higher	  gradients	  (mean	  
gradient	  33±15	  mmHg	  vs.	  22±7	  mmHg,	  p<0.01).	  Among	  patients	  with	  LVEF	  recovery	  96.7%	  
were	  candidates	  for	  definitive	  treatment	  (53.4%	  TAVI,	  43.3%	  AVR)	  vs.	  21.4%	  (all	  TAVI)	  in	  




Patients	  with	  MVR. Within	  the	  33	  patients	  with	  MVR	  grade	  ≥3,	  a	  significant	  reduction	  of	  
MVR	  grade	  was	  observed	  in	  17	  (51.5%),	  whereas	  in	  16	  patients	  (48.5%)	  there	  were	  no	  relevant	  
changes.	  There	  were	  no	  significant	  differences	  between	  patients	  who	  improved	  MVR	  grade	  
and	  those	  who	  did	  not,	  with	  the	  notable	  exception	  of	  AVA	  after	  BAV	  (0.89±0.21mm2	  vs.	  
0.72±0.17	  mm2,	  p=0.045).	  Changes	  in	  MVR	  grade	  and	  final	  heart	  team	  decision	  is	  illustrated	  in	  
figure	  3.	  Overall,	  70.5%	  of	  patients	  with	  MVR	  grade	  reduction	  were	  addressed	  to	  definitive	  
treatment	  (52.9%	  TAVI,	  17.6%	  AVR)	  vs.	  31.3%	  of	  patients	  whitout	  MVR	  grade	  improvement	  
(p=0.02). 
Patients	  with	  hemodynamic	  instability. Among	  103	  patients,	  9	  (8.7%)	  presented	  with	  
cardiogenic	  shock,	  44	  (42.7%)	  with	  acute	  pulmonary	  edema	  at	  the	  time	  of	  BAV,	  and	  50	  (48.6%)	  
with	  NYHA	  class	  IV.	  Eight	  patients	  (7.8%)	  died	  in-­‐hospital.	  Among	  the	  95	  remaining	  patients,	  21	  
(22.1%)	  were	  candidates	  for	  AVR,	  57	  (60%)	  for	  TAVI	  and	  17	  (17.9%)	  for	  MT/BAV.	  	  
Frailty. Thirteen	  patients	  were	  classified	  as	  fragile	  according	  to	  previously	  mentioned	  criteria.	  
They	  must	  be	  fragile	  enough	  to	  be	  considered	  ineligible	  for	  definitive	  treatment	  at	  the	  time	  of	  
BTD	  but	  not	  so	  fragile	  to	  be	  directly	  addressed	  to	  a	  MT/BAV	  strategy.	  Among	  them,	  6	  patients	  
(46.1%)	  finally	  underwent	  TAVI,	  3	  AVR	  (23.1%)	  and	  4	  (30.8%)	  MT/BAV. 
Comorbidity. Among	  47	  patients	  with	  relevant	  comorbidity	  and	  potentially	  reversible	  
conditions,	  34	  (72.3%)	  received	  BAV	  as	  bridge	  to	  urgent	  non	  cardiac	  surgery,	  5	  had	  severe	  
pulmonary	  hypertension	  (10.6%),	  and	  8	  patients	  had	  multiple	  comorbidities	  (17%).	  After	  BTD	  
BAV,	  25	  (53.2%)	  were	  addressed	  to	  MT/BAV,	  7	  to	  TAVI	  (14.9%),	  and	  15	  (31.9%)	  to	  AVR.   
Whole	  BTD	  population. Of	  the	  193	  patients	  with	  BTD-­‐BAV	  who	  received	  a	  second	  heart	  
team	  evaluation,	  49	  (25.4%)	  were	  finally	  deemed	  eligible	  for	  AVR,	  91	  (47.2%)	  for	  TAVI,	  and	  the	  
remaining	  53	  (27.5%)	  were	  deemed	  ineligible	  for	  definitive	  treatment	  and	  were	  candidates	  for	  




	  	   At	  multivariable	  analyses,	  the	  independent	  predictors	  for	  definitive	  treatment	  of	  aortic	  
stenosis	  were	  age	  (HR	  0.93;	  95%	  CI	  0.88-­‐0.99),	  body	  mass	  index	  (HR	  1.09;	  95%	  CI	  1.01-­‐1.18),	  
coronary	  artery	  disease	  (HR	  3.37;	  95%	  CI	  1.58-­‐7.21),	  mean	  gradient	  before	  BAV	  (HR	  1.03;	  CI	  
95%	  1.00-­‐1.05)	  and	  hemodynamic	  instability	  (HR	  2.54;	  CI	  95%	  1.21-­‐5.33).	  
Discussion	  
This	  study	  explored	  the	  role	  of	  BAV	  as	  bridge-­‐to-­‐decision	  in	  high-­‐risk	  patients	  with	  severe	  
aortic	  stenosis	  who	  presented	  cardiac	  or	  extra-­‐cardiac	  conditions	  necessitating	  further	  
evaluation	  by	  the	  heart	  team.	  The	  rationale	  behind	  such	  a	  strategy	  is	  twofold:	  helping	  the	  
heart	  team	  to	  choose	  the	  best	  therapeutic	  option	  for	  each	  patient;	  avoiding	  futile	  procedures	  
in	  patients	  who	  would	  probably	  not	  have	  prognostic	  benefit	  from	  definitive	  treatment	  of	  aortic	  
stenosis.	  Our	  investigation	  suggests	  that,	  in	  this	  patient	  population,	  BTD	  BAV	  is	  safe	  and	  might	  
have	  relevant	  impact	  on	  final	  decision-­‐making.	  
	   Whilst	  many	  high-­‐risk	  patients	  can	  be	  safely	  addressed	  to	  AVR10	  or	  TAVI11-­‐13	  following	  
accurate	  multidisciplinary	  evaluation,	  in	  some	  instances	  additional	  information	  may	  be	  needed	  
to	  complete	  the	  diagnostic	  workout.	  Indeed	  multiple	  factors	  influence	  symptoms,	  life	  
expectancy	  and	  final	  outcomes	  of	  invasive	  procedures	  in	  elderly	  patients	  with	  severe	  aortic	  
stenosis	  and	  relevant	  comorbidity.	  Thus,	  not	  surprisingly,	  our	  study	  population	  was	  quite	  
heterogeneous.	  In	  this	  context,	  the	  second	  heart	  team	  evaluation	  around	  1	  month	  after	  BTD	  
BAV	  generated	  a	  true	  differentiation	  of	  final	  therapeutic	  decision	  between	  TAVI,	  AVR	  and	  
MT/BAV,	  and	  our	  data	  show	  that	  clinical	  and/or	  laboratory	  changes	  occurred	  after	  BTD	  BAV	  
were	  actually	  meaningful	  for	  decision-­‐making.	  For	  example,	  patients	  who	  showed	  significant	  
LVEF	  recovery	  and/or	  MVR	  grade	  reduction	  after	  BTD-­‐BAV	  were	  significantly	  more	  likely	  to	  be	  
candidates	  for	  definitive	  AS	  treatment	  in	  comparison	  with	  patients	  not	  showing	  significant	  
changes.	  Likewise,	  BTD-­‐BAV	  was	  very	  helpful	  in	  patients	  with	  hemodynamic	  instability,	  with	  




treatments.	  More	  challenging	  is	  the	  interpretation	  of	  results	  in	  patients	  classified	  as	  fragile	  or	  
with	  relevant	  comorbidity,	  maybe	  because	  this	  post-­‐hoc	  classification	  could	  only	  partially	  rely	  
on	  objective	  data.	  Yet,	  69.2%	  of	  very	  fragile	  patients	  and	  46.8%	  of	  the	  patients	  with	  severe	  or	  
multiple	  comorbidity	  were	  finally	  recommended	  for	  definitive	  AS	  treatment,	  mainly	  on	  the	  
grounds	  of	  some	  clinical	  improvement.	  
	   There	  is	  growing	  utilization	  of	  BAV	  as	  a	  bridge	  to	  TAVI	  or	  AVR14-­‐19.	  However,	  within	  this	  
patient	  group,	  roughly	  2	  additional	  subgroups	  can	  be	  distinguished:	  1)	  patients	  undergoing	  
BAV	  to	  palliate	  symptoms	  and	  reducing	  operative	  risk	  while	  they	  are	  screened	  and	  await	  
definitive	  therapy,	  which	  has	  been	  already	  planned	  (“true”	  bridge-­‐to-­‐TAVI	  or	  bridge-­‐to-­‐AVR);	  
2)	  patients	  undergoing	  BAV	  as	  a	  preliminary	  treatment	  strategy	  to	  choose	  the	  best	  therapeutic	  
option,	  because	  there	  is	  the	  need	  to	  assess	  the	  potential	  benefit	  of	  valve	  replacement	  before	  
committing	  to	  the	  procedural	  risk	  (bridge-­‐to-­‐decision).	  Our	  study	  is	  the	  first	  investigation	  
specifically	  focused	  on	  this	  last	  peculiar	  BAV	  indication.	  	  
	  	   Previous	  studies	  have	  shown	  an	  improvement	  of	  LVEF	  after	  BAV20,	  and	  an	  association	  
between	  LVEF	  recover	  after	  BAV	  and	  prognosis	  post-­‐TAVI21,22.	  Dobutamine	  stress	  
echocardiography	  is	  commonly	  recommended	  to	  evaluate	  contractile	  reserve	  in	  patients	  with	  
severe	  AS	  and	  reduced	  LVEF	  undergoing	  surgical	  or	  percutaneous	  aortic	  valve	  replacement.	  
Nevertheless,	  BAV	  may	  provide	  complimentary	  information	  beyond	  contractile	  reserve21.	  In	  
our	  view,	  this	  is	  particularly	  evident	  when	  there	  are	  other	  concomitant	  conditions	  potentially	  
associated	  with	  adverse	  prognosis	  or	  lack	  of	  symptoms	  relief.	  It	  has	  been	  previously	  reported	  
that	  nearly	  half	  of	  patients	  with	  severe	  AS	  and	  coexistent	  MVR	  showed	  a	  reduction	  in	  the	  
magnitude	  of	  MVR	  after	  BAV23;	  our	  study	  reproduced	  very	  closely	  those	  figures	  (51.5%	  
significant	  MVR	  reduction).	  A	  reduction	  in	  pulmonary	  artery	  systolic	  pressure	  can	  be	  observed	  
in	  around	  half	  of	  the	  patients24.	  Additional	  insights	  can	  be	  provided	  by	  BTD	  BAV	  when	  an	  
unstable	  hemodynamic	  state	  may	  preclude	  a	  thorough	  patient	  evaluation.	  Finally,	  in	  patients	  




severe	  lung	  disease,	  BTD	  BAV	  may	  be	  important	  to	  estimate	  the	  potential	  benefit	  of	  valve	  
replacement.	  In	  fact,	  severe	  comorbidity	  is	  often	  determinant	  to	  deny	  AVR,	  but	  is	  also	  strongly	  
affecting	  mid-­‐	  and	  long-­‐term	  prognosis	  after	  TAVI	  22,25,26,	  and	  BTD	  BAV	  may	  be	  a	  useful	  tool	  to	  
improve	  risk	  stratification.	  
	   This	  is	  a	  retrospective,	  nonrandomized,	  single-­‐center	  study,	  and	  all	  our	  findings	  should	  
be	  interpreted	  cautiously.	  Study	  population	  was	  quite	  heterogeneous,	  and	  classification	  into	  
subgroups	  of	  interest	  was	  arbitrarily	  done	  post-­‐hoc.	  Even	  recognizing	  that	  more	  data	  occur,	  
consistency	  with	  findings	  from	  other	  investigations	  and	  the	  relatively	  large	  number	  of	  patients	  
included	  in	  the	  present	  analysis	  are	  noteworthy.	  
Conclusion	  
Balloon	  aortic	  valvuloplasty	  should	  be	  considered	  as	  bridge-­‐to-­‐decision	  in	  high-­‐risk	  patients	  














Demographics	   	  
	   Age,	  yrs	   81	  ±	  7	  
	   Male	  gender	   89	  (44.1)	  
	   Body	  mass	  index,	  kg/m2	   24.9	  ±	  	  4.7	  
	   	   BMI≤20	   25	  (12.4%)	  
Risk	  Factors	   	  
	   Diabetes	   63	  (31.2)	  
	   Hypertension	   161	  (79.7)	  
	   Dyslipidemia	   109	  (54.0)	  
Clinical	  history	   	  
	   Previous	  myocardial	  infarction	  	   51	  (25.2)	  
	   Previous	  percutaneous	  coronary	  intervention	   32	  (15.8)	  
	   Previous	  coronary	  artery	  bypass	  graft	   18	  (8.9)	  
	   Previous	  cardiac	  surgery	   20	  (9.9)	  
Previous	  cerebrovascular	  accident	   28	  (13.9)	  
Comorbidity	   	  
	   Coronary	  artery	  disease	   87	  (43.1	  %)	  
	   Chronic	  kidney	  disease	   163	  (80.7	  %)	  
	   	   GFR<30	  ml/min/1.73	  m2	   	  55	  (27.2	  %)	  
Chronic	  obstructive	  pulmonary	  disease	  	   261	  (29.2%)	  
Pulmonary	  hypertension	   5	  (13.9	  %)	  
Clinical	  presentation	   	  
	   Dyspnea	   189	  (93.6)	  
	  	  	   	   NYHA	  I-­‐	  II	   28	  (14.8	  %)	  
	  	  	   	   NYHA	  	  III-­‐IV	   161	  (85.2%)	  
Stable	  angina	   47	  (23.3	  %)	  
	   Syncope	   21	  (10.4	  %)	  
	   Cardiogenic	  shock	   9	  (4.5)	  





Data	  are	  shown	  as	  mean	  ±	  standard	  deviation	  	  for	  continuous	  variables	  and	  absolute	  numbers	  (%)	  for	  dichotomous	  variables.	  	  
BMI=	  body	  mass	  index;	  EuroSCORE=	  european	  system	  for	  cardiac	  operative	  risk	  evaluation;	  GFR=	  glomerular	  filtration	  rate;	  




Table	  2. Echocardiographic	  parameters	  before	  and	  after	  balloon	  valvuloplasty. 





AVA,	  cm2	   0.66	  ±	  0.17	   0.84	  ±	  0.24	   <0.01	  
Mean	  transvalvular	  gradient,	  mmHg	   47	  ±	  17	   33	  ±	  14	   <0.01	  
Max	  gradient,	  mmHg	   76	  ±	  27	   55	  ±	  23	   <0.01	  
Aortic	  regurgitation	   	   	   <0.01	  
	   ≤1+	   148	  (73.3)	   88	  (59.4)	   	  
	   2+	   48	  (24.7)	   53	  (35.8)	   	  
	   ≥3+	   6	  (3.0)	   7	  (4.7)	   	  
Mitral	  valve	  regurgitation	   	   	   0.51	  
	   ≤1+	   119	  (58.9)	   89	  (60.1)	  	   	  
	   2+	   50	  (24.7)	   42	  (28.4)	   	  
	   ≥3+	   33	  (16.3)	   17	  (11.5)	   	  










Death	   9	  (4.5)	  
	   Cardiac	   8	  (4.0)	  
	   Non	  cardiac	   1	  (0.5)	  
Acute	  myocardial	  infarction	   0	  	  
Cerebrovascular	  accident	   2	  (1.0)	  
	   Transient	  ischemic	  attack	   0	  
	   Stroke	   2	  (1.0)	  
	   	   Disabling	   1	  (0.5)	  
	   	   Non	  disabling	   1	  (0.5)	  
Vascular	  complications	   8	  (4.0)	  
	   Major	   1	  (0.5)	  
	   Minor	   7	  (3.5)	  
Vascular	  complication	  description	   	  
	   Access-­‐site	  hematoma	   5	  (2.5)	  
	   Retroperitoneal	  hematoma	   0	  
	   Artero-­‐venous	  fistula	   0	  
	   Femoral	  dissection	   1	  (0.5)	  
	   Femoral	  pseudo-­‐aneurysm	   2	  (1.0)	  
	   Thrombosis	   0	  





Table	  4.	  Independent	  predictors	  for	  definitive	  treatment	  of	  aortic	  stenosis.	  	  
	   Univariate	  analysis	   Multivariate	  analysis†	  
Variable	   HR	   95%	  CI	   p	   HR	   95%	  CI	   p	  
Age,	  yrs	   0.95	   0.90-­‐0.99	   0.02	   0.93	   0.88-­‐0.99	   0.021	  
Body	  mass	  index,	  kg/m2	   1.07	   1.00-­‐1.14	   0.04	   1.09	   1.01-­‐1.18	   0.028	  
Coronary	  artery	  disease	   3.74	   1.89-­‐7.38	   0.0001	   3.37	   1.58-­‐7.21	   0.002	  
Chronic	  kidney	  disease	   0.43	   0.18-­‐1.03	   0.06	   	   	   	  
Dyspnea	   2.84	   0.91-­‐8.84	   0.07	   	   	   	  
Stable	  angina	   2.19	   0.99-­‐4.88	   0.05	   	   	   	  
MVR	  grade≥3	  (before	  
BAV)	   0.40	  
0.19-­‐0.85	   0.018	   	   	   	  
MVR	  grade	  <3	  (after	  
BAV)*	   5.28	  
1.20-­‐23.31	   0.028	   	   	   	  
Mean	  gradient	  before	  
BAV	   1.02	  
1.00-­‐1.04	   0.09	   1.03	   1.00-­‐1.05	   0.017	  
Hemodynamic	  instability	   1.86	   1.01-­‐3.42	   0.05	   2.54	   1.21-­‐5.33	   0.014	  
LVEF	  recover*	   15.5	   3.76-­‐63.5	   <0.0001	   	   	   	  
*Variables	  not	  tested	  in	  the	  multivariate	  analysis	  because	  they	  refer	  only	  to	  specific	  patient	  subgroups	  and	  are	  not	  applicable	  to	  
the	  entire	  population;	  
†
C	  statistic=0.74;	  Hosmer	  and	  Lemeshow	  goodness-­‐of-­‐fit	  test	  p=0.23	  





























Figure 1. * 41 patients presents >1 conditions 	  	  
*41	  patients	  presented	  more	  than	  1	  condition	  
	  
FIGURE	  1.	  	  
Study	  flow.	  Selection	  and	  classification	  of	  patients	  who	  underwent	  balloon	  aortic	  valvuloplasty	  (BAV)	  as	  
bridge-­‐to-­‐decision.	  AVR=	  aortic	  valve	  replacement;	  LVEF=	  left	  ventricular	  ejection	  fraction;	  MVR=	  mitral	  





























FIGURE	  2.	  	  
Effect	  of	  bridge-­‐to-­‐decision	  balloon	  aortic	  valvuloplasty	  on	  decision	  making	  in	  patients	  with	  reduced	  
left	  ventricular	  ejection	  fraction.	  
Proportion	  of	  patients	  with	  or	  without	  significant	  recover	  of	  left	  ventricular	  ejection	  fraction	  (LVEF)	  who	  
were	  candidates	  for	  different	  definitive	  treatment	  of	  aortic	  stenosis	  after	  balloon	  aortic	  valvuloplasty.	  
AVR=	  aortic	  valve	  replacement;	  MT/BAV=	  medical	  treatment/repeat	  balloon	  aortic	  valvuloplasty;	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FIGURE	  3.	  	  
Effect	  of	  bridge-­‐to-­‐decision	  balloon	  aortic	  valvuloplasty	  on	  decision	  making	  in	  patients	  with	  moderate	  
to	  severe	  mitral	  valve	  regurgitation.	  
Changes	  in	  mitral	  valve	  regurgitation	  (MVR)	  grade	  after	  balloon	  aortic	  valvuloplasty	  and	  effect	  on	  final	  
decision	  making	  by	  the	  heart	  team.	  AVR=	  aortic	  valve	  replacement;	  MT/BAV=	  medical	  treatment/repeat	  










Figure 4. FIGURE	  4.	  	  
Effect	  of	  bridge-­‐to-­‐decision	  balloon	  aortic	  valvuloplasty	  on	  decision	  making	  in	  the	  whole	  study	  
population.	  
Outcome	  of	  the	  second	  heart	  team	  evaluation	  in	  patients	  who	  underwent	  bridge-­‐to-­‐balloon	  balloon	  
aortic	  valvuloplasty.	  AVR=	  aortic	  valve	  replacement;	  MT/BAV=	  medical	  treatment/repeat	  balloon	  aortic	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